Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Andreas Kristo
Andreas Kristo

Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis

Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis
Artiva Biotherapeutics targets pivotal trial

Artiva Biotherapeutics, Inc. has announced a focused strategy to advance its AlloNK therapy as it prepares for its first Phase 3 registrational trial. The company is positioning AlloNK as a potential deep B-cell depletion treatment for patients with refractory rheumatoid arthritis, a group for whom current medical options often fall short.

By orienting development around this critical late-stage study, Artiva Biotherapeutics signals a commitment to bringing innovative solutions to a challenging segment of the autoimmune disease market. Further updates on the trial timeline and patient recruitment are expected in future announcements.

Artiva previously reported initial positive results for AlloNK and announced plans to advance to a Phase 3 rheumatoid arthritis trial in 2026, according to a company update. CEO Fred Aslan is scheduled to discuss progress on the Phase 3 program at the 2026 Jefferies Healthcare Conference, the company said in a recent statement. The upcoming trial will focus on patients with refractory disease.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Buterin’s new vision: Why Ethereum wants to become digital gold
  • By Olena Litvinenko
  • 6 hours ago
Buterin’s new vision: Why Ethereum wants to become digital gold
Editors' Picks
From affair to market crash: How the Nvidia scandal hit Bitcoin
  • By Anastasiia Chabaniuk
  • 10 hours ago
From affair to market crash: How the Nvidia scandal hit Bitcoin
Editors' Picks
Shield AI’s Echodyne deal and the global counter-drone race
  • By Dmytro Kharkov
  • 11 hours ago
Shield AI’s Echodyne deal and the global counter-drone race
Editors' Picks
All Editors' Top Picks

Latest Artiva News

Artiva Biotherapeutics discontinues AlloNK development and reviews strategic alternatives
  • By Ksenia Gerey
  • 27.10.2026
Artiva Biotherapeutics discontinues AlloNK development and reviews strategic alternatives
Companies
#Artiva
AlloNK plus rituximab delivers clinically meaningful gains in early Sjögren disease study, Artiva Biotherapeutics finds
  • By Ksenia Gerey
  • 01.10.2026
AlloNK plus rituximab delivers clinically meaningful gains in early Sjögren disease study, Artiva Biotherapeutics finds
Companies
#Artiva
Artiva Biotherapeutics, Inc. early AlloNK plus rituximab results show outpatient potential
  • By Andreas Kristo
  • 26.08.2026
Artiva Biotherapeutics, Inc. early AlloNK plus rituximab results show outpatient potential
Companies
#Artiva
All Artiva News
  • Olena Litvinenko
  • 6 hours ago
Buterin’s new vision: Why Ethereum wants to become digital gold
  • Anastasiia Chabaniuk
  • 10 hours ago
From affair to market crash: How the Nvidia scandal hit Bitcoin
  • Dmytro Kharkov
  • 11 hours ago
Shield AI’s Echodyne deal and the global counter-drone race
  • Pavlo Kot
  • Yesterday
From airline tickets to Ferraris: What can you buy with crypto?
  • Pavlo Kot
  • 07.11.2026
Apartment or Bitcoin: Choosing a safe haven for your wealth
  • Daria Chernytska
  • 9 min ago
Alexander Stahel: Nvidia seen as crucial for U.S., South Korean, and Taiwanese stock markets
  • Alena Volkova
  • 14 min ago
Honda Canada will expand hybrid and gasoline vehicle output at Alliston facilities, Colin D'Mello reports
  • Mykhailo Ihnatenko
  • 22 min ago
Alex Bosworth: LN protocol is shifting toward selective node operations
  • Elena Nikulina
  • 24 min ago
Audited 42% non-compounded ROR over 17 years disclosed, Peter Brandt notes
  • Igor Krasulya
  • 34 min ago
$3,000 transfer threshold dates to 1995 and is unindexed, Michael A. Gayed notes
Top News
  • Ksenia Gerey
  • 4 hours ago
Anthropic has no plans to delay IPO despite market selloff
Anthropic has no plans to delay IPO despite market selloff
  • Eugene Komchuk
  • 6 hours ago
Hedge funds begin massive selloff of technology stocks
Hedge funds begin massive selloff of technology stocks
  • Oleg Tkachenko
  • 8 hours ago
U.S. authorities grant Coinbase a banking charter
U.S. authorities grant Coinbase a banking charter
  • Olga Shendetskaya
  • 9 hours ago
Oil prices fall after Trump's comments on Iran
Oil prices fall after Trump's comments on Iran
  • Pavlo Kot
  • 11 hours ago
Binance, Tether and Trump-linked crypto firms face congressional scrutiny
Binance, Tether and Trump-linked crypto firms face congressional scrutiny
Live News
  • Mélissa Bac
  • Now
Strategy buys $82 million in Bitcoin, raises holdings to 850,364 BTC
  • Mykhailo Ihnatenko
  • Now
Nvidia stock falls amid CEO scrutiny: Can buyers reclaim $178?
  • Anton Kharitonov
  • Now
EUR/USD targets 1.1200 as dollar weakens ahead of U.S. inflation data
  • Mykhailo Ihnatenko
  • Now
Ethereum slides as geopolitical risks trigger another $1B liquidation wave
  • Pavlo Kot
  • Now
Binance hackers still hold $3.1 billion in cryptocurrency after attack
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers